A Randomized, Double-Blind, Placebo- Controlled, Multicentre Phase III Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for12 weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain.
- Year: 2006
- Type: Pharmaceutical - Pain
- Phase: III
- Indication: Pain - General
